Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lakewood Amedex

Explore full profile

Lakewood-Amedex Inc, a development-stage biopharmaceutical company,

Bradenton, United StatesFounded 2006Biotech & Life Sciences
Valuation $233K Market cap · 2026

About Lakewood Amedex

Lakewood Amedex, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics. The company primarily serves healthcare providers and institutions that require advanced solutions for treating infections, particularly those resistant to conventional antibiotics. Operating in the pharmaceutical and biotechnology market, Lakewood Amedex leverages its proprietary Bisphosphocin technology to disrupt microbial cell membranes, leading to the rapid and safe eradication of infections.

Read full description

The business model revolves around the research, development, and commercialization of these novel therapeutics. Revenue is generated through licensing agreements, partnerships with larger pharmaceutical companies, and eventually, direct sales of approved products. The company's leadership team, with over 100 years of combined industry experience, is well-equipped to navigate the complex regulatory landscape and bring these innovative solutions to market efficiently.

Lakewood Amedex's flagship product, Bisphosphocin Nu 8, is currently advancing through IND enabling studies for the treatment of complicated urinary tract infections. The company aims to address significant unmet medical needs, reduce hospital stays, and lower healthcare costs by providing effective treatments for chronic diabetic foot ulcers, oral infections, and cystic fibrosis-related infections.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2006
Headquarters
Bradenton, United States
Listing
IPO 2026
Sector
Biotech & Life Sciences

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Scarsdale Equities
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States50%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lakewood Amedex on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lakewood Amedex on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.